Does Medicaid Cover Ketamine Therapy? Coverage by Program

In most states, Medicaid does not routinely cover ketamine therapy for depression, anxiety, or PTSD because these are off-label uses that the U.S. Food and Drug Administration has not specifically approved. There is an important exception: Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression, is covered by many state Medicaid programs when strict criteria are met. Coverage varies dramatically from state to state, so the honest answer is "sometimes, and it depends." Below, we explain what Medicaid generally pays for, how coverage differs by program, and the practical steps to confirm your own benefits.

How ketamine therapy Medicaid coverage actually works

Medicaid is a joint federal-and-state program, which means each state designs its own benefit rules within federal guidelines. That structure is the single biggest reason ketamine therapy Medicaid coverage is so inconsistent. Two factors drive most coverage decisions:

• FDA approval status. Medicaid plans strongly favor FDA-approved, on-label treatments. Spravato (esketamine) carries FDA approval for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder and acute suicidal ideation. Generic intravenous (IV) ketamine for psychiatric use is considered off-label.
• Setting and billing codes. Even when a drug isn't covered, related services—such as a psychiatric evaluation, an office visit, or monitoring—may be billable. Some patients find that parts of their care are reimbursed even when the ketamine itself is not.

Because of this, it is common for IV ketamine infusions to be paid entirely out of pocket while a Spravato course is partially or fully covered through the same Medicaid plan.

Spravato (esketamine) vs. IV ketamine under Medicaid

Feature	Spravato (esketamine)	IV / compounded ketamine
FDA approval for depression	Yes (treatment-resistant depression)	No (off-label)
Typical Medicaid coverage	Often covered with prior authorization	Rarely covered
Common requirements	Failed 2+ antidepressants; in-office administration; monitoring	Varies; usually self-pay
Where administered	Certified REMS healthcare setting	Clinic or, in some models, telehealth-guided at home

Coverage by Medicaid program type

Your specific plan matters as much as your state. Most enrollees fall into one of these categories:

• Fee-for-service (traditional) Medicaid. The state pays providers directly. Spravato coverage typically follows the state's published drug formulary and prior-authorization rules.
• Medicaid managed care organizations (MCOs). Most enrollees are in private plans contracted by the state. Each MCO may have its own formulary, preferred providers, and authorization process, so two people in the same state can have different coverage.
• Dual eligibility (Medicare + Medicaid). If you qualify for both, Medicare may be the primary payer. Spravato is often processed under Medicare Part B because it is administered in a clinical setting, with Medicaid potentially covering remaining costs.

State approaches also differ widely. Some state Medicaid programs publish clear esketamine policies with defined criteria; others handle requests case by case. You can read more about how location shapes your options on our state access hub.

Common requirements for approval

When a Medicaid plan does cover esketamine, it usually requires prior authorization. Documentation typically includes:

1. A diagnosis of treatment-resistant depression, generally defined as an inadequate response to two or more antidepressants taken at adequate dose and duration.
2. Administration at a certified treatment site enrolled in the medication's REMS safety program.
3. Concurrent use of an oral antidepressant in many cases.
4. Periodic documentation that the treatment is helping, to continue authorization.

These criteria reflect how the medication was studied; research suggests esketamine can help some people who have not responded to standard antidepressants, but individual results vary.

What if Medicaid won't cover it?

If your plan denies coverage for ketamine therapy, you still have options:

• Request the written policy and appeal. Ask your plan for its medical policy on esketamine and the specific denial reason. Medicaid enrollees have appeal rights, and denials are sometimes overturned with stronger documentation from your prescriber.
• Ask about the covered alternative. If IV ketamine is denied, your clinician may be able to pursue Spravato, which has a clearer coverage path.
• Compare self-pay pricing. Many telehealth and in-clinic providers publish transparent cash prices. Our cost and insurance guides break down typical price ranges and questions to ask.
• Look into manufacturer or clinic assistance. Some programs offer financial help for eligible patients.

If you're weighing providers, our provider comparisons can help you evaluate cost, format, and credentials side by side, and our conditions hub explains which diagnoses are most often treated.

How to confirm your own coverage

Coverage details change, and the only reliable answer comes from your plan. Take these steps:

1. Call the member services number on your Medicaid or MCO card and ask specifically about "esketamine (Spravato)" and "ketamine infusion" coverage.
2. Ask whether prior authorization is required and what documentation is needed.
3. Confirm whether the provider you're considering is in-network and enrolled in the REMS program.
4. Get any coverage confirmation in writing before scheduling treatment.

This article is patient education, not medical or insurance advice. Coverage rules vary by state, plan, and year—always verify directly with your Medicaid plan and discuss treatment decisions with a licensed clinician.

Frequently Asked Questions

Does Medicaid cover ketamine infusions for depression?

Usually no. IV ketamine for depression is an off-label use that most Medicaid plans do not cover, so infusions are often paid out of pocket. The FDA-approved nasal spray Spravato (esketamine) has a much better chance of coverage.

Is Spravato covered by Medicaid?

Often yes, but with conditions. Many state Medicaid programs and managed care plans cover Spravato for treatment-resistant depression when prior authorization criteria are met, such as having failed two or more antidepressants and receiving it at a certified site.

Why does Medicaid ketamine coverage vary so much by state?

Medicaid is administered by each state within federal rules, so formularies, prior-authorization criteria, and managed care contracts differ. Two people in different states—or even different plans in the same state—can have very different coverage.

What can I do if Medicaid denies my ketamine therapy?

Request the written denial reason and the plan's medical policy, then file an appeal with supporting documentation from your prescriber. You can also ask about the covered Spravato pathway or compare transparent self-pay pricing among providers.